Seaport Therapeutics Winds Up USD 225Mn Series B Financing Round

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round. Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well as other new investors

Seaport Therapeutics, (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, recently announced the closing of an oversubscribed $225 million Series B financing round.  According to Industry sources, this syndicate was powered by General Atlantic, a leading global growth investor, with participation from funds […]